Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director | May 21, 2026 | May 26, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Patient Officer | February 15, 2019 | March 06, 2019 |
| Lunai Bioworks Inc.RENB · Entity 7981 | Director | June 25, 2024 | June 27, 2024 |
| NOVAVAX INCNVAX · Entity 4632 | Director | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.69 · Expires 2036-05-21 | Direct | 12,500 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 12,500 · Balance 12,500 F1: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date.
GILEAD SCIENCES, INC.
Report date February 15, 2019 · Filed March 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,046 |
Reported balance
After 2019-02-15 transaction · row 1
1 source rowRow 1 · 2019-02-15 · Grant · Acquired 330 · Balance 58,046 F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.01 · Expires 2029-03-01 | Direct | 9,640 |
Reported balance
After 2019-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-01 · Grant · Acquired 9,640 · Balance 9,640 F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 15,530 |
Reported balance
After 2019-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-01 · Grant · Acquired 1,890 · Balance 15,530 F3: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
F3: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F4: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.
Lunai Bioworks Inc.
Report date June 25, 2024 · Filed June 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase shares of common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2034-06-25 | Direct | 48,137 |
Reported balance
After 2024-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-25 · Grant · Acquired 48,137 · Balance 48,137 |
NOVAVAX INC
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,685 |
Reported balance
After 2026-06-20 transaction · row 1
1 source rowRow 1 · 2026-06-20 · Exercise / conversion · Acquired 18,880 · Balance 47,685 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.13 · Expires 2036-06-18 | Direct | 21,270 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 21,270 · Balance 21,270 F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,180 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 14,180 · Balance 14,180 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-20 · Exercise / conversion · Disposed 18,880 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2026 Filed Jun 23, 2026 23:51 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 18,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-076924 · tm2618639-3_4seq1.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,880 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F4 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date F4 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date Read SEC document |
| June 20, 2026 Filed Jun 23, 2026 23:51 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 18,880 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-076924 · tm2618639-3_4seq1.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 23:51 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 14,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-076924 · tm2618639-3_4seq1.xml · derivative · entry 3 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,180 Underlying: Common Stock · 14,180 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 23:51 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 21,270 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-26-076924 · tm2618639-3_4seq1.xml · derivative · entry 2 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,270 Underlying: Common Stock · 21,270 shares Expires 2036-06-18 F2 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| May 21, 2026 Filed May 26, 2026 21:39 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $59.69 | $0.00 |
DisclosureSEC source: 0001193125-26-239714 · ownership.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2036-05-21 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:36 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 18,884 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-062192 · tm2518838-2_4seq1.xml · derivative · entry 2 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,884 Underlying: Common Stock · 18,884 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2024 grant date subject to continued service on the Company's Board of Directors through the vesting date. F2 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2024 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:36 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 28,326 | $6.42 Strike: $6.42 | $181,852.92 |
DisclosureSEC source: 0001104659-25-062192 · tm2518838-2_4seq1.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,326 Underlying: Common Stock · 28,326 shares Expires 2035-06-20 F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 20, 2024 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:09 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 10,420 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000783 · primary_01.xml · derivative · entry 2 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,420 shares Expires 2034-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:09 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 10,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000783 · primary_01.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 00:40 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0000950170-25-085754 · ownership.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of June 10, 2025 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date. Read SEC document |
| December 31, 2024 Filed Feb 6, 2025 00:06 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantCommon Stock | 1,982 | $8.61 | $17,065.02 |
DisclosureSEC source: 0001104659-25-009786 · tm255659-2_4seq1.xml · nonDerivative · entry 4 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,385 Read SEC document |
| September 30, 2024 Filed Feb 6, 2025 00:06 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantCommon Stock | 1,311 | $12.77 | $16,741.47 |
DisclosureSEC source: 0001104659-25-009786 · tm255659-2_4seq1.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,403 Read SEC document |
| June 30, 2024 Filed Feb 6, 2025 00:06 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantCommon Stock | 1,202 | $13.93 | $16,743.86 |
DisclosureSEC source: 0001104659-25-009786 · tm255659-2_4seq1.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,092 Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 22:53 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 48,137 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001731122-24-001031 · ownership.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,137 Underlying: Common stock · 48,137 shares Expires 2034-06-25 Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:11 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 10,420 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-000864 · primary_01.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,420 Underlying: Common Stock · 10,420 shares Expires 2034-06-12 Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:11 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 15,630 | $15.86 Strike: $15.86 | $247,891.80 |
DisclosureSEC source: 0001593968-24-000864 · primary_01.xml · derivative · entry 3 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,630 Underlying: Common Stock · 15,630 shares Expires 2034-06-12 Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:11 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 6,670 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-000864 · primary_01.xml · derivative · entry 2 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,670 shares Expires 2033-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:11 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 6,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-000864 · primary_01.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2024 Filed May 21, 2024 22:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $28.09 | $0.00 |
DisclosureSEC source: 0000950170-24-063166 · ownership.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-16 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 17, 2024 over a one-year period. Read SEC document |
| March 31, 2024 Filed Feb 6, 2025 00:06 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantCommon Stock | 3,420 | $4.90 | $16,758.00 |
DisclosureSEC source: 0001104659-25-009786 · tm255659-2_4seq1.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,220 Read SEC document |
| December 27, 2023 Filed Feb 2, 2024 17:14 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 23,810 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001731122-24-000185 · ownership.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,810 Underlying: Common stock · 23,810 shares Expires 2033-12-27 Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:43 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 6,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036741 · doc4.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,670 Underlying: Common Stock · 6,670 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F4 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date. F4 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:43 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 7,710 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-23-036741 · doc4.xml · derivative · entry 3 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,710 Underlying: Common Stock · 7,710 shares Expires 2033-06-12 F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the the Plan will vest one (1) year from the June 12, 2023 grant date (the "Grant Date") subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 10, 2023 Filed Jun 13, 2023 20:43 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 3,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036741 · doc4.xml · derivative · entry 2 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), vested on the first anniversary of the June 10, 2022 grant date subject to continued service on the Company's Board of Directors through the vesting date. F2 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), vested on the first anniversary of the June 10, 2022 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 10, 2023 Filed Jun 13, 2023 20:43 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 3,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-036741 · doc4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| May 19, 2023 Filed May 23, 2023 21:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $24.10 | $0.00 |
DisclosureSEC source: 0000899243-23-013739 · doc4.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-18 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 19, 2023 over a one-year period. Read SEC document |
| December 27, 2022 Filed Jan 5, 2023 21:48 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 57,252 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001731122-23-000021 · ownership.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,252 Underlying: Common stock · 57,252 shares Expires 2032-12-27 Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 00:45 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038590 · doc4.xml · derivative · entry 2 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 17, 2021 grant date subject to continued service on the Company's Board of Directors through the vesting date. F2 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 17, 2021 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 00:45 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-038590 · doc4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 21:06 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 3,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036745 · doc4.xml · derivative · entry 2 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,100 Underlying: Common Stock · 3,100 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date. F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 21:06 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 4,600 | $0.00 Strike: $40.62 | $0.00 |
DisclosureSEC source: 0001209191-22-036745 · doc4.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600 Underlying: Common Stock · 4,600 shares Expires 2032-06-10 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") will vest one (1) year from the June 10, 2022 grant date (the "Grant Date") subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 21:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $20.84 | $0.00 |
DisclosureSEC source: 0000899243-22-020701 · doc4.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-30 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 31, 2022 over a one-year period. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 02:41 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 9,458 | $0.00 Strike: $7.93 | $0.00 |
DisclosureSEC source: 0001731122-21-002209 · ownership.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,458 Underlying: Common stock · 9,458 shares Expires 2031-12-27 Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 21:15 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-042449 · doc4.xml · derivative · entry 2 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 Underlying: Common Stock · 700 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date. F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 21:15 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 1,300 | $0.00 Strike: $179.89 | $0.00 |
DisclosureSEC source: 0001209191-21-042449 · doc4.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Underlying: Common Stock · 1,300 shares Expires 2031-06-17 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") will vest one (1) year from the June 17, 2021 grant date (the "Grant Date") subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| May 26, 2021 Filed May 28, 2021 21:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $21.45 | $0.00 |
DisclosureSEC source: 0000899243-21-021144 · doc4.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 26, 2021 over a one-year period. Read SEC document |
| December 28, 2020 Filed Dec 22, 2021 16:10 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 25,424 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001731122-21-002176 · ownership.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,424 Underlying: Common stock · 25.424 shares Expires 2030-12-28 F1 · shares: On December 3, 2020, Mr. Alton was granted an option to purchase 25,424 shares of common stock of Enochian Biosciences Inc., said option to vest on December 28, 2021. Read SEC document |
| October 31, 2020 Filed Nov 3, 2020 23:15 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to buy) · Derivative | 7,700 | $0.00 Strike: $80.71 | $0.00 |
DisclosureSEC source: 0001209191-20-056737 · doc4.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2030-10-31 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, will vest one (1) year from the October 31, 2020 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| May 27, 2020 Filed May 29, 2020 23:22 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $15.15 | $0.00 |
DisclosureSEC source: 0000899243-20-014627 · doc4.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-05-26 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 27, 2020 over a one-year period. Read SEC document |
| April 06, 2020 Filed Dec 22, 2021 16:10 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 15,625 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001731122-21-002176 · ownership.xml · derivative · entry 2 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common stock · 15,625 shares Expires 2030-04-06 F2 · shares: On April 6, 2020, Mr. Alton was granted an option to purchase 15,625 shares of common stock of Enochian Biosciences Inc., said option to vest on December 27, 2020. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 22:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $10.48 | $0.00 |
DisclosureSEC source: 0000899243-20-008294 · doc4.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-03-12 F1 · derivative.exercise_date: Shares subject to the stock option vest and become exercisable with respect to 25% of the shares on the first anniversary of the date of grant and, thereafter, at the rate of 2.08334% of the total number of shares per month, until fully vested and exercisable on the fourth anniversary of the date of grant, subject to the Reporting Person's continued service. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 00:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 1,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-010115 · form4.xml · derivative · entry 3 Alton Gregg H · CIK 0001334682 · Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,530 Underlying: Common Stock · 1,890 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 00:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 9,640 | $0.00 Strike: $66.01 | $0.00 |
DisclosureSEC source: 0001127602-19-010115 · form4.xml · derivative · entry 2 Alton Gregg H · CIK 0001334682 · Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,640 Underlying: Common Stock · 9,640 shares Expires 2029-03-01 F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| February 15, 2019 Filed Mar 6, 2019 00:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 330 | $57.45 | $18,959.00 |
DisclosureSEC source: 0001127602-19-010115 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,046 F1 · shares: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 23:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 13,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-004871 · form4.xml · derivative · entry 5 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,640 Underlying: Common Stock · 13,640 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 23:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 63,100 | $0.00 Strike: $68.75 | $0.00 |
DisclosureSEC source: 0001127602-19-004871 · form4.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,100 Underlying: Common Stock · 63,100 shares Expires 2029-02-06 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 23:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 5,861 | $68.75 | $402,943.75 |
DisclosureSEC source: 0001127602-19-004871 · form4.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,716 Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 23:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 9,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-004871 · form4.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,577 F5 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2016. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 23:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 10,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-004871 · form4.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,535 F4 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017, and February 1, 2018. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 00:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 17,250 | $0.00 Strike: $40.56 | $0.00 |
DisclosureSEC source: 0001127602-18-010234 · form4.xml · derivative · entry 5 Alton Gregg H · CIK 0001334682 · EVP,Corporate &Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,596 Underlying: Common Stock · 17,250 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.